The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2017
Filed:
Nov. 05, 2013
Applicant:
Commissariat À L'energie Atomique ET Aux Energies Alternatives (Cea), Paris, FR;
Inventors:
Stéphane Prost, Malabry, FR;
Marek Kirszenbaum, Vanves, FR;
Mikael Le Dantec, Paris, FR;
Philippe Rousselot, Paris, FR;
Philippe Leboulch, Charlestown, MA (US);
Assignee:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61K 31/404 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/496 (2006.01); A61K 31/5025 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/404 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01);
Abstract
Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARγ agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause relapse.